Search

Your search keyword '"Kiemeney, Lambertus"' showing total 34 results
Start Over Author "Kiemeney, Lambertus" Journal european urology
34 results on '"Kiemeney, Lambertus"'

2. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights

Author

Koutros, Stella, Kiemeney, Lambertus A., Pal Choudhury, Parichoy, Milne, Roger L., Lopez de Maturana, Evangelina, Ye, Yuanqing, Joseph, Vijai, Florez-Vargas, Oscar, Dyrskjøt, Lars, Figueroa, Jonine, Dutta, Diptavo, Giles, Graham G., Hildebrandt, Michelle A.T., Offit, Kenneth, Kogevinas, Manolis, Weiderpass, Elisabete, McCullough, Marjorie L., Freedman, Neal D., Albanes, Demetrius, Kooperberg, Charles, Cortessis, Victoria K., Karagas, Margaret R., Johnson, Alison, Schwenn, Molly R., Baris, Dalsu, Furberg, Helena, Bajorin, Dean F., Cussenot, Olivier, Cancel-Tassin, Geraldine, Benhamou, Simone, Kraft, Peter, Porru, Stefano, Carta, Angela, Bishop, Timothy, Southey, Melissa C., Matullo, Giuseppe, Fletcher, Tony, Kumar, Rajiv, Taylor, Jack A., Lamy, Philippe, Prip, Frederik, Kalisz, Mark, Weinstein, Stephanie J., Hengstler, Jan G., Selinski, Silvia, Harland, Mark, Teo, Mark, Kiltie, Anne E., Tardón, Adonina, Serra, Consol, Carrato, Alfredo, García-Closas, Reina, Lloreta, Josep, Schned, Alan, Lenz, Petra, Riboli, Elio, Brennan, Paul, Tjønneland, Anne, Otto, Thomas, Ovsiannikov, Daniel, Volkert, Frank, Vermeulen, Sita H., Aben, Katja K., Galesloot, Tessel E., Turman, Constance, De Vivo, Immaculata, Giovannucci, Edward, Hunter, David J., Hohensee, Chancellor, Hunt, Rebecca, Patel, Alpa V., Huang, Wen-Yi, Thorleifsson, Gudmar, Gago-Dominguez, Manuela, Amiano, Pilar, Golka, Klaus, Stern, Mariana C., Yan, Wusheng, Liu, Jia, Li, Shengchao Alfred, Katta, Shilpa, Hutchinson, Amy, Hicks, Belynda, Wheeler, William A., Purdue, Mark P., McGlynn, Katherine A., Kitahara, Cari M., Haiman, Christopher A., Greene, Mark H., Rafnar, Thorunn, Chatterjee, Nilanjan, Chanock, Stephen J., Wu, Xifeng, Real, Francisco X., Silverman, Debra T., Garcia-Closas, Montserrat, Stefansson, Kari, Prokunina-Olsson, Ludmila, Malats, Núria, and Rothman, Nathaniel

Published
2023
Full Text
View/download PDF

3. Erratum to “European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel” [Eur. Urol. 79(4) (2021) 480–488]

Author

Sylvester, Richard J., primary, Rodríguez, Oscar, additional, Hernández, Virginia, additional, Turturica, Diana, additional, Bauerová, Lenka, additional, Max Bruins, Harman, additional, Bründl, Johannes, additional, van der Kwast, Theo H., additional, Brisuda, Antonin, additional, Rubio-Briones, José, additional, Seles, Maximilian, additional, Hentschel, Anouk E., additional, Kusuma, Venkata R.M., additional, Huebner, Nicolai, additional, Cotte, Juliette, additional, Mertens, Laura S., additional, Volanis, Dimitrios, additional, Cussenot, Olivier, additional, Subiela Henríquez, Jose D., additional, de la Peña, Enrique, additional, Pisano, Francesca, additional, Pešl, Michael, additional, van der Heijden, Antoine G., additional, Herdegen, Sonja, additional, Zlotta, Alexandre R., additional, Hacek, Jaromir, additional, Calatrava, Ana, additional, Mannweiler, Sebastian, additional, Bosschieter, Judith, additional, Ashabere, David, additional, Haitel, Andrea, additional, Côté, Jean-François, additional, El Sheikh, Soha, additional, Lunelli, Luca, additional, Algaba, Ferran, additional, Alemany, Isabel, additional, Soria, Francesco, additional, Runneboom, Willemien, additional, Breyer, Johannes, additional, Nieuwenhuijzen, Jakko A., additional, Llorente, Carlos, additional, Molinaro, Luca, additional, Hulsbergen-van de Kaa, Christina A., additional, Evert, Matthias, additional, Kiemeney, Lambertus A.L.M., additional, N'Dow, James, additional, Plass, Karin, additional, Čapoun, Otakar, additional, Soukup, Viktor, additional, Dominguez-Escrig, Jose L., additional, Cohen, Daniel, additional, Palou, Joan, additional, Gontero, Paolo, additional, Burger, Maximilian, additional, Zigeuner, Richard, additional, Mostafid, Amir Hugh, additional, Shariat, Shahrokh F., additional, Rouprêt, Morgan, additional, Compérat, Eva M., additional, Babjuk, Marko, additional, and van Rhijn, Bas W.G., additional

Published
2023
Full Text
View/download PDF

4. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study

Author

Bancroft, Elizabeth K., Page, Elizabeth C., Castro, Elena, Lilja, Hans, Vickers, Andrew, Sjoberg, Daniel, Assel, Melissa, Foster, Christopher S., Mitchell, Gillian, Drew, Kate, Mæhle, Lovise, Axcrona, Karol, Evans, D. Gareth, Bulman, Barbara, Eccles, Diana, McBride, Donna, van Asperen, Christi, Vasen, Hans, Kiemeney, Lambertus A., Ringelberg, Janneke, Cybulski, Cezary, Wokolorczyk, Dominika, Selkirk, Christina, Hulick, Peter J., Bojesen, Anders, Skytte, Anne-Bine, Lam, Jimmy, Taylor, Louise, Oldenburg, Rogier, Cremers, Ruben, Verhaegh, Gerald, van Zelst-Stams, Wendy A., Oosterwijk, Jan C., Blanco, Ignacio, Salinas, Monica, Cook, Jackie, Rosario, Derek J., Buys, Saundra, Conner, Tom, Ausems, Margreet G., Ong, Kai-ren, Hoffman, Jonathan, Domchek, Susan, Powers, Jacquelyn, Teixeira, Manuel R., Maia, Sofia, Foulkes, William D., Taherian, Nassim, Ruijs, Marielle, den Enden, Apollonia T. Helderman-van, Izatt, Louise, Davidson, Rosemarie, Adank, Muriel A., Walker, Lisa, Schmutzler, Rita, Tucker, Kathy, Kirk, Judy, Hodgson, Shirley, Harris, Marion, Douglas, Fiona, Lindeman, Geoffrey J., Zgajnar, Janez, Tischkowitz, Marc, Clowes, Virginia E., Susman, Rachel, Ramón y Cajal, Teresa, Patcher, Nicholas, Gadea, Neus, Spigelman, Allan, van Os, Theo, Liljegren, Annelie, Side, Lucy, Brewer, Carole, Brady, Angela F., Donaldson, Alan, Stefansdottir, Vigdis, Friedman, Eitan, Chen-Shtoyerman, Rakefet, Amor, David J., Copakova, Lucia, Barwell, Julian, Giri, Veda N., Murthy, Vedang, Nicolai, Nicola, Teo, Soo-Hwang, Greenhalgh, Lynn, Strom, Sara, Henderson, Alex, McGrath, John, Gallagher, David, Aaronson, Neil, Ardern-Jones, Audrey, Bangma, Chris, Dearnaley, David, Costello, Philandra, Eyfjord, Jorunn, Rothwell, Jeanette, Falconer, Alison, Gronberg, Henrik, Hamdy, Freddie C., Johannsson, Oskar, Khoo, Vincent, Kote-Jarai, Zsofia, Lubinski, Jan, Axcrona, Ulrika, Melia, Jane, McKinley, Joanne, Mitra, Anita V., Moynihan, Clare, Rennert, Gad, Suri, Mohnish, Wilson, Penny, Killick, Emma, Moss, Sue, and Eeles, Rosalind A.

Published
2014
Full Text
View/download PDF

6. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel

Author

Sylvester, Richard J., primary, Rodríguez, Oscar, additional, Hernández, Virginia, additional, Turturica, Diana, additional, Bauerová, Lenka, additional, Bruins, Harman Max, additional, Bründl, Johannes, additional, van der Kwast, Theo H., additional, Brisuda, Antonin, additional, Rubio-Briones, José, additional, Seles, Maximilian, additional, Hentschel, Anouk E., additional, Kusuma, Venkata R.M., additional, Huebner, Nicolai, additional, Cotte, Juliette, additional, Mertens, Laura S., additional, Volanis, Dimitrios, additional, Cussenot, Olivier, additional, Subiela Henríquez, Jose D., additional, de la Peña, Enrique, additional, Pisano, Francesca, additional, Pešl, Michael, additional, van der Heijden, Antoine G., additional, Herdegen, Sonja, additional, Zlotta, Alexandre R., additional, Hacek, Jaromir, additional, Calatrava, Ana, additional, Mannweiler, Sebastian, additional, Bosschieter, Judith, additional, Ashabere, David, additional, Haitel, Andrea, additional, Côté, Jean-François, additional, El Sheikh, Soha, additional, Lunelli, Luca, additional, Algaba, Ferran, additional, Alemany, Isabel, additional, Soria, Francesco, additional, Runneboom, Willemien, additional, Breyer, Johannes, additional, Nieuwenhuijzen, Jakko A., additional, Llorente, Carlos, additional, Molinaro, Luca, additional, Hulsbergen-van de Kaa, Christina A., additional, Evert, Matthias, additional, Kiemeney, Lambertus A.L.M., additional, N’Dow, James, additional, Plass, Karin, additional, Čapoun, Otakar, additional, Soukup, Viktor, additional, Dominguez-Escrig, Jose L., additional, Cohen, Daniel, additional, Palou, Joan, additional, Gontero, Paolo, additional, Burger, Maximilian, additional, Zigeuner, Richard, additional, Mostafid, Amir Hugh, additional, Shariat, Shahrokh F., additional, Rouprêt, Morgan, additional, Compérat, Eva M., additional, Babjuk, Marko, additional, and van Rhijn, Bas W.G., additional

Published
2021
Full Text
View/download PDF

14. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Author

Page, Elizabeth C., primary, Bancroft, Elizabeth K., additional, Brook, Mark N., additional, Assel, Melissa, additional, Hassan Al Battat, Mona, additional, Thomas, Sarah, additional, Taylor, Natalie, additional, Chamberlain, Anthony, additional, Pope, Jennifer, additional, Raghallaigh, Holly Ni, additional, Evans, D. Gareth, additional, Rothwell, Jeanette, additional, Maehle, Lovise, additional, Grindedal, Eli Marie, additional, James, Paul, additional, Mascarenhas, Lyon, additional, McKinley, Joanne, additional, Side, Lucy, additional, Thomas, Tessy, additional, van Asperen, Christi, additional, Vasen, Hans, additional, Kiemeney, Lambertus A., additional, Ringelberg, Janneke, additional, Jensen, Thomas Dyrsø, additional, Osther, Palle J.S., additional, Helfand, Brian T., additional, Genova, Elena, additional, Oldenburg, Rogier A., additional, Cybulski, Cezary, additional, Wokolorczyk, Dominika, additional, Ong, Kai-Ren, additional, Huber, Camilla, additional, Lam, Jimmy, additional, Taylor, Louise, additional, Salinas, Monica, additional, Feliubadaló, Lidia, additional, Oosterwijk, Jan C., additional, van Zelst-Stams, Wendy, additional, Cook, Jackie, additional, Rosario, Derek J., additional, Domchek, Susan, additional, Powers, Jacquelyn, additional, Buys, Saundra, additional, O'Toole, Karen, additional, Ausems, Margreet G.E.M., additional, Schmutzler, Rita K., additional, Rhiem, Kerstin, additional, Izatt, Louise, additional, Tripathi, Vishakha, additional, Teixeira, Manuel R., additional, Cardoso, Marta, additional, Foulkes, William D., additional, Aprikian, Armen, additional, van Randeraad, Heleen, additional, Davidson, Rosemarie, additional, Longmuir, Mark, additional, Ruijs, Mariëlle W.G., additional, Helderman van den Enden, Apollonia T.J.M., additional, Adank, Muriel, additional, Williams, Rachel, additional, Andrews, Lesley, additional, Murphy, Declan G., additional, Halliday, Dorothy, additional, Walker, Lisa, additional, Liljegren, Annelie, additional, Carlsson, Stefan, additional, Azzabi, Ashraf, additional, Jobson, Irene, additional, Morton, Catherine, additional, Shackleton, Kylie, additional, Snape, Katie, additional, Hanson, Helen, additional, Harris, Marion, additional, Tischkowitz, Marc, additional, Taylor, Amy, additional, Kirk, Judy, additional, Susman, Rachel, additional, Chen-Shtoyerman, Rakefet, additional, Spigelman, Allan, additional, Pachter, Nicholas, additional, Ahmed, Munaza, additional, Ramon y Cajal, Teresa, additional, Zgajnar, Janez, additional, Brewer, Carole, additional, Gadea, Neus, additional, Brady, Angela F., additional, van Os, Theo, additional, Gallagher, David, additional, Johannsson, Oskar, additional, Donaldson, Alan, additional, Barwell, Julian, additional, Nicolai, Nicola, additional, Friedman, Eitan, additional, Obeid, Elias, additional, Greenhalgh, Lynn, additional, Murthy, Vedang, additional, Copakova, Lucia, additional, Saya, Sibel, additional, McGrath, John, additional, Cooke, Peter, additional, Rønlund, Karina, additional, Richardson, Kate, additional, Henderson, Alex, additional, Teo, Soo H., additional, Arun, Banu, additional, Kast, Karin, additional, Dias, Alexander, additional, Aaronson, Neil K., additional, Ardern-Jones, Audrey, additional, Bangma, Chris H., additional, Castro, Elena, additional, Dearnaley, David, additional, Eccles, Diana M., additional, Tricker, Karen, additional, Eyfjord, Jorunn, additional, Falconer, Alison, additional, Foster, Christopher, additional, Gronberg, Henrik, additional, Hamdy, Freddie C., additional, Stefansdottir, Vigdis, additional, Khoo, Vincent, additional, Lindeman, Geoffrey J., additional, Lubinski, Jan, additional, Axcrona, Karol, additional, Mikropoulos, Christos, additional, Mitra, Anita, additional, Moynihan, Clare, additional, Rennert, Gadi, additional, Suri, Mohnish, additional, Wilson, Penny, additional, Dudderidge, Tim, additional, Offman, Judith, additional, Kote-Jarai, Zsofia, additional, Vickers, Andrew, additional, Lilja, Hans, additional, and Eeles, Rosalind A., additional

Published
2019
Full Text
View/download PDF

15. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

Author

Cumberbatch, Marcus George Kwesi, primary, Jubber, Ibrahim, additional, Black, Peter C., additional, Esperto, Francesco, additional, Figueroa, Jonine D., additional, Kamat, Ashish M., additional, Kiemeney, Lambertus, additional, Lotan, Yair, additional, Pang, Karl, additional, Silverman, Debra T., additional, Znaor, Ariana, additional, and Catto, James W.F., additional

Published
2018
Full Text
View/download PDF

16. Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients

Author

Gontero, Paolo, primary, Sylvester, Richard, additional, Pisano, Francesca, additional, Joniau, Steven, additional, Vander Eeckt, Kathy, additional, Serretta, Vincenzo, additional, Larré, Stéphane, additional, Di Stasi, Savino, additional, Van Rhijn, Bas, additional, Witjes, Alfred J., additional, Grotenhuis, Anne J., additional, Kiemeney, Lambertus A., additional, Colombo, Renzo, additional, Briganti, Alberto, additional, Babjuk, Marek, additional, Malmström, Per-Uno, additional, Oderda, Marco, additional, Irani, Jacques, additional, Malats, Nuria, additional, Baniel, Jack, additional, Mano, Roy, additional, Cai, Tommaso, additional, Cha, Eugene K., additional, Ardelt, Peter, additional, Varkarakis, John, additional, Bartoletti, Riccardo, additional, Spahn, Martin, additional, Johansson, Robert, additional, Frea, Bruno, additional, Soukup, Viktor, additional, Xylinas, Evanguelos, additional, Dalbagni, Guido, additional, Karnes, R. Jeffrey, additional, Shariat, Shahrokh F., additional, and Palou, Joan, additional

Published
2015
Full Text
View/download PDF

18. Epidemiology and Risk Factors of Urothelial Bladder Cancer

Author

Burger, Maximilian, primary, Catto, James W.F., additional, Dalbagni, Guido, additional, Grossman, H. Barton, additional, Herr, Harry, additional, Karakiewicz, Pierre, additional, Kassouf, Wassim, additional, Kiemeney, Lambertus A., additional, La Vecchia, Carlo, additional, Shariat, Shahrokh, additional, and Lotan, Yair, additional

Published
2013
Full Text
View/download PDF

20. The Epidemiology of Renal Cell Carcinoma

Author

Ljungberg, Börje, primary, Campbell, Steven C., additional, Cho, Han Yong, additional, Jacqmin, Didier, additional, Lee, Jung Eun, additional, Weikert, Steffen, additional, and Kiemeney, Lambertus A., additional

Published
2011
Full Text
View/download PDF

29. Low–Dose Oxybutynin for the Treatment of Urge Incontinence: Good Efficacy and Few Side Effects

Author

Bemelmans, Bart L.H., Kiemeney, Lambertus A.L.M., and Debruyne, Frans M.J.

Abstract

Objective:Oxybutynin is an efficacious pharmacotherapeutic agent for the treatment of urge incontinence. However, many patients discontinue therapy because of the considerable side effects. This study aims at assessing the efficacy of a low–dose oxybutynin (2.5 mg three times daily) in relation to the concomitant profile of side effects.Methods:Unselected primary care practice patients with involuntary urine loss were eligible for this study. A specially designed questionnaire was used to establish the diagnosis of symptomatic urge incontinence. All patients started with an oral dose of oxybutynin of 2.5 mg three times daily, and the responses with regard to efficacy and side effects were assessed after 2 and 6 weeks. Efficacy was evaluated using subjective patients’ impression as well as data extracted from their voiding diaries. Adverse events possibly related to the use of oxybutynin were specifically asked for. Patients who experienced little or no symptomatc relief and who experienced no side effects were given a higher dose (5 mg three times daily). Results:General practitioners recruited 416 patients with symptomatic urge incontinence. Increasing the dose to 5 mg three times was preferred by 115 patients (28%). After 6 weeks 393 patients reported a partial or complete symptomatic cure (positive responder rate 95%). The average number of micturitions per 24 h decreased from 9.9±(SD)3.7 to 6.0±2.5 (p<0.001), and the average number of episodes of urine loss per 24 h decreased from 6.0±3.6 to 1.7±1.8 (p<0.001). A total of 123 patients (30%) reported side effects attributable to the use of oxybutynin; 42 patients (10%) had to stop the medication because of the severity of these side effects. Conclusion:Successful pharmacological treatment of symptomatic urge incontinence can be given in a primary care setting using oxybutynin. Starting with a low dose of 2.5 three times daily, a subjective and objective efficacy can be achieved with fewer side effects than reported in the literature.

Published
2000
Full Text
View/download PDF

30. The Predictive Value of p53, p27Kip1, and α-Catenin for Progression in Superficial Bladder Carcinoma

Author

Schrier, Barthold Ph., Vriesema, Jessica L.J., Witjes, J. Alfred, Kiemeney, Lambertus A.L.M., and Schalken, Jack A.

Subjects
*CANCER, *CELL cycle, *CELL adhesion, *BLADDER diseases, *IMMUNOHISTOCHEMISTRY, *LOGISTIC regression analysis, *PROGNOSIS
Abstract

Abstract: Objective: The aim of the study was to confirm the predictive value of cell cycle regulatory proteins, p53 and p27kip1, and the cell adhesion complex protein α-catenin, for progression in patients with superficial bladder carcinoma. Methods: Forty-one patients with progression after primary superficial bladder carcinoma were individually matched to patients with nonprogressive superficial bladder carcinoma. Matching was done for sex, age, tumor stage and grade, concomitant carcinoma in situ (CIS), and duration of follow-up. Immunohistochemical analysis of p53, p27kip1, and α-catenin was performed on each primary bladder tumor. Analysis for the p53 mutation was done on 41 bladder tumor samples. Conditional logistic regression analysis was used to establish the prognostic value of immunohistochemical p53, p27kip1, and α-catenin status. Results: The independent odds ratios for progression were 0.3 (95% confidence interval [CI], 0.1–1.2) for high-risk p27kip1, 3.4 (95%CI, 0.8–15.2) for high-risk p53, and 2.5 (95%CI, 0.6–10.3) for high-risk α-catenin. Combinations of different markers had no synergistic effects. Two p53 mutations were found in 21 DNA samples analyzed from nonprogressive tumors (9.5%); 8 of 20 samples (40%) from progressive tumors showed a p53 mutation. The probability of high-risk p53 immunostaining was 5-fold increased in case of mutations in p53. The estimated positive predictive value of high-risk p53 or high-risk α-catenin was about 23%. Conclusions: We confirm that high-risk p53, p53 mutation, and α-catenin immunohistochemistry do have an additional prognostic value in primary bladder carcinoma. However, the clinical value of the investigated parameters remains limited. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

31. DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

Author

Hessels, Daphne, Klein Gunnewiek, Jacqueline M.T., van Oort, Inge, Karthaus, Herbert F.M., van Leenders, Geert J.L., van Balken, Bianca, Kiemeney, Lambertus A., Witjes, J. Alfred, and Schalken, Jack A.

Subjects
*CANCER patients, *PROSTATE cancer, *RNA, *URINALYSIS, *TISSUES
Abstract

Background: DD3PCA3 is the most prostate cancer-specific gene described to date. To assess the clinical utility of DD3PCA3 a time-resolved fluorescence-based, quantitative RT-PCR analysis for DD3PCA3 was developed.Methods: The diagnostic potential of DD3PCA3 was determined by quantitative measurement of DD3PCA3 transcripts in non-malignant and malignant prostate specimens. Moreover, DD3PCA3 transcripts were determined quantitatively in urine sediments obtained after prostatic massage. A cohort of 108 men, admitted for prostate biopsies based on a PSA of >3 ng/ml, was studied.Results: Prostate tumors showed a 66-fold up-regulation of DD3PCA3 (median 158.4·105 copies/μg tissue RNA) when compared to benign prostate tissue (median 2.4·105 copies/μg tissue RNA). This up-regulation was found in more than 95% of prostate cancer specimens studied. These data revealed that specimens with less than 10% of cancer cells could be accurately discriminated from non-cancer tissues. Hence, detection of a small fraction of prostate cancer cells in a background of normal cells seemed feasible. Therefore, this DD3PCA3-based RT-PCR assay was used for the identification of prostate cancer in urine sediments obtained after prostatic massage. From 108 men with a serum PSA value >3 ng/ml, 24 men were shown to have prostate cancer upon biopsy. Of these 24 men, 16 were shown to be positive for DD3PCA3, indicating a sensitivity of the assay of 67%. Furthermore, a negative predictive value of 90% was calculated.Conclusion: The quantitative RT-PCR assay for DD3PCA3 described, bears great promise as a tool for molecular urine analysis. It has great potential in reducing the number of unnecessary biopsies. A multi-center study using this DD3PCA3 assay can provide the basis for the utility of molecular diagnostics in clinical urological practice. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

32. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients

Author

Marco Oderda, Anne J. Grotenhuis, Joan Palou, Alfred Witjes, Roy Mano, Bas W.G. van Rhijn, Robert Johansson, Bruno Frea, Richard Sylvester, S. Larrè, Shahrokh F. Shariat, P.-U. Malmström, Kathy Vander Eeckt, J. Varkarakis, Viktor Soukup, Evanguelos Xylinas, Núria Malats, Lambertus A. Kiemeney, Alberto Briganti, Martin Spahn, Eugene K. Cha, Riccardo Bartoletti, Savino M. Di Stasi, Jacques Irani, T. Tony Cai, R. Jeffrey Karnes, Steven Joniau, Guido Dalbagni, Marek Babjuk, Paolo Gontero, Jack Baniel, P. Ardelt, Vincenzo Serretta, Renzo Colombo, Francesca Pisano, Gontero, Paolo, Sylvester, Richard, Pisano, Francesca, Joniau, Steven, Vander Eeckt, Kathy, Serretta, Vincenzo, Larré, Stéphane, Di Stasi, Savino, Van Rhijn, Ba, Witjes, Alfred J., Grotenhuis, Anne J., Kiemeney, Lambertus A., Colombo, Renzo, Briganti, Alberto, Babjuk, Marek, Malmström, Per-Uno, Oderda, Marco, Irani, Jacque, Malats, Nuria, Baniel, Jack, Mano, Roy, Cai, Tommaso, Cha, Eugene K., Ardelt, Peter, Varkarakis, John, Bartoletti, Riccardo, Spahn, Martin, Johansson, Robert, Frea, Bruno, Soukup, Viktor, Xylinas, Evanguelo, Dalbagni, Guido, Karnes, R. Jeffrey, Shariat, Shahrokh F., Palou, Joan, Gontero, P, Sylvester, R, Pisano, F, Joniau, S, Eeckt, KV, Serretta, V, Larré, S, Di Stasi, S, Van Rhijn g, B, Witjes, AJ, Grotenhuis, AJ, Kiemeney, LA, Colombo, R, Alberto Briganti, A, Babjuk , M, Malmstrom, PU, Oderda, M, Irani, J, Nuria Malats, N, Baniel, J, Mano, R, Cai, T, Cha, EK, Ardelt, P, Varkarakis, J, Bartoletti, R, Spahn, M, Johansson, R, Frea , B, Soukup, V, Xylinas, E, Dalbagni, G, Karnes RJ, Shariat SF, and Palou, J

Subjects
Oncology, Male, Non–muscle-invasive bladder, Bacillus Calmette-Guerin, BCG, Non-muscle-invasive bladder cancer, Prognostic factors, T1G3, Settore MED/24 - Urologia, Risk groups, Retrospective Studie, Risk Factors, Age Factor, skin and connective tissue diseases, Bacillus (shape), Prognostic factor, biology, Bacillus Calmette-Gue´rin, BCG, Non–muscle-invasive bladder cancer, Prognostic factors, T1G3, Age Factors, Bacillus Calmette-Gue´rin, Middle Aged, Prognosis, Tumor Burden, Bacillu, Survival Rate, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Urinary Bladder Neoplasm, BCG Vaccine, Disease Progression, Female, Non muscle invasive, Calmette-Guérin, Carcinoma in Situ, Human, medicine.medical_specialty, Prognosi, Urology, Cystectomy, Risk Assessment, Non–muscle-invasive bladder cancer, Follow-Up Studie, Adjuvants, Immunologic, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, cancer, Humans, Aged, Retrospective Studies, Bladder cancer, business.industry, Risk Factor, biology.organism_classification, medicine.disease, Multicenter study, Urinary Bladder Neoplasms, Proper treatment, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Contains fulltext : 153742.pdf (Publisher’s version ) (Closed access) BACKGROUND: The impact of prognostic factors in T1G3 non-muscle-invasive bladder cancer (BCa) patients is critical for proper treatment decision making. OBJECTIVE: To assess prognostic factors in patients who received bacillus Calmette-Guerin (BCG) as initial intravesical treatment of T1G3 tumors and to identify a subgroup of high-risk patients who should be considered for more aggressive treatment. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2451 T1G3 patients from 23 centers who received BCG between 1990 and 2011. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Using Cox multivariable regression, the prognostic importance of several clinical variables was assessed for time to recurrence, progression, BCa-specific survival, and overall survival (OS). RESULTS AND LIMITATIONS: With a median follow-up of 5.2 yr, 465 patients (19%) progressed, 509 (21%) underwent cystectomy, and 221 (9%) died because of BCa. In multivariable analyses, the most important prognostic factors for progression were age, tumor size, and concomitant carcinoma in situ (CIS); the most important prognostic factors for BCa-specific survival and OS were age and tumor size. Patients were divided into four risk groups for progression according to the number of adverse factors among age >/= 70 yr, size >/= 3 cm, and presence of CIS. Progression rates at 10 yr ranged from 17% to 52%. BCa-specific death rates at 10 yr were 32% in patients >/= 70 yr with tumor size >/= 3 cm and 13% otherwise. CONCLUSIONS: T1G3 patients >/= 70 yr with tumors >/= 3 cm and concomitant CIS should be treated more aggressively because of the high risk of progression. PATIENT SUMMARY: Although the majority of T1G3 patients can be safely treated with intravesical bacillus Calmette-Guerin, there is a subgroup of T1G3 patients with age >/= 70 yr, tumor size >/= 3 cm, and concomitant CIS who have a high risk of progression and thus require aggressive treatment.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results